Close Menu

NEW YORK (GenomeWeb) – Exact Sciences reported after the close of the market on Thursday that its first quarter revenues rose 87 percent year over year, thanks to a corresponding 87 percent increase in testing volumes for its Cologuard noninvasive colon cancer screening test.

For the three months ended March 31, the molecular diagnostics company reported revenues of $90.3 million, up from $48.4 million in Q1 2017, and beating analysts' average estimate of $86.9 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times Magazine examines gender discrimination at the Salk Institute.

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.